DDInter434 DDInter706
Colistimethate is an antibiotic that has been shown to have bactericidal activity against aerobic gram-negative microorganisms. Colistimethate is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa.
Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.
Colistimethate {u} (Compound) resembles {v} (Compound) Polymyxin B
Polymyxin B {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Colistimethate {u} (Compound) resembles {v} (Compound) Bacitracin
Bacitracin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Colistimethate {u} (Compound) resembles {v} (Compound) Polymyxin B
Polymyxin B {u} (Compound) resembles {v} (Compound) Octreotide
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Colistimethate {u} (Compound) resembles {v} (Compound) Bacitracin
Bacitracin {u} (Compound) resembles {v} (Compound) Octreotide
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Colistimethate {u} (Compound) resembles {v} (Compound) Polymyxin B
Polymyxin B {u} may lead to a major life threatening interaction when taken with {v} Plazomicin
Plazomicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Colistimethate {u} (Compound) is included by {v} (Pharmacologic Class) Polymyxins
Polymyxins {u} (Pharmacologic Class) includes {v} (Compound) Polymyxin B
Polymyxin B {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Colistimethate {u} (Compound) resembles {v} (Compound) Colistin
Colistin {u} (Compound) resembles {v} (Compound) Polymyxin B
Polymyxin B {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Colistimethate {u} (Compound) resembles {v} (Compound) Bacitracin
Bacitracin {u} may lead to a major life threatening interaction when taken with {v} Plazomicin
Plazomicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Colistimethate {u} (Compound) resembles {v} (Compound) Polymyxin B
Polymyxin B {u} may lead to a major life threatening interaction when taken with {v} Neomycin
Neomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Colistimethate {u} (Compound) causes {v} (Side Effect) Protein urine present
Protein urine present {u} (Side Effect) is caused by {v} (Compound) Levonorgestrel
Levonorgestrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Colistimethate (Compound) resembles Polymyxin B (Compound) and Polymyxin B may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Colistimethate (Compound) resembles Bacitracin (Compound) and Bacitracin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Colistimethate (Compound) resembles Polymyxin B (Compound) and Polymyxin B (Compound) resembles Octreotide (Compound) and Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Colistimethate (Compound) resembles Bacitracin (Compound) and Bacitracin (Compound) resembles Octreotide (Compound) and Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Colistimethate (Compound) resembles Polymyxin B (Compound) and Polymyxin B may lead to a major life threatening interaction when taken with Plazomicin and Plazomicin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Colistimethate (Compound) is included by Polymyxins (Pharmacologic Class) and Polymyxins (Pharmacologic Class) includes Polymyxin B (Compound) and Polymyxin B may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Colistimethate (Compound) resembles Colistin (Compound) and Colistin (Compound) resembles Polymyxin B (Compound) and Polymyxin B may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Colistimethate (Compound) resembles Bacitracin (Compound) and Bacitracin may lead to a major life threatening interaction when taken with Plazomicin and Plazomicin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Colistimethate (Compound) resembles Polymyxin B (Compound) and Polymyxin B may lead to a major life threatening interaction when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Colistimethate (Compound) causes Protein urine present (Side Effect) and Protein urine present (Side Effect) is caused by Levonorgestrel (Compound) and Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Exenatide